144 related articles for article (PubMed ID: 24281198)
1. Distal phalangeal necrosis in the extremities as a paraneoplastic syndrome in prostate cancer: an extremely rare case.
Akin Y; Yucel S; Baykara M
Urol Int; 2014; 93(2):244-6. PubMed ID: 24281198
[TBL] [Abstract][Full Text] [Related]
2. Fulminant digital necrosis in a patient with prostate adenocarcinoma.
Paolini MV; Jankilevich G; Graziano C; Fernández Romero DS
Allergol Immunopathol (Madr); 2010; 38(1):48-50. PubMed ID: 19836875
[No Abstract] [Full Text] [Related]
3. Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer Aggravated by Steroid Therapy.
Kang MK; Park JG; Lee HJ
Med Princ Pract; 2018; 27(2):197-200. PubMed ID: 29320775
[TBL] [Abstract][Full Text] [Related]
4. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with prostatic carcinoma.
Yalçin S; Erman M; Tekuzman G; Ruacan S
Am J Clin Oncol; 2000 Aug; 23(4):384-5. PubMed ID: 10955869
[TBL] [Abstract][Full Text] [Related]
5. Papuloerythroderma of Ofuji.
Li S; Yu X; Wang T
JAMA Dermatol; 2020 Dec; 156(12):1365. PubMed ID: 33052383
[No Abstract] [Full Text] [Related]
6. Phalangeal microgeodic disease: report of two cases and review of imaging.
Lee RK; Griffith JF; Read JW; Ng AW; Bellemore M
Skeletal Radiol; 2013 Mar; 42(3):451-5. PubMed ID: 23296552
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic neurological and hematological syndromes associated with prostate cancer.
Gakiya M; Naka H; Saito S
Int J Urol; 2012 May; 19(5):471-4. PubMed ID: 22220977
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic syndromes in prostate cancer.
Hong MK; Kong J; Namdarian B; Longano A; Grummet J; Hovens CM; Costello AJ; Corcoran NM
Nat Rev Urol; 2010 Dec; 7(12):681-92. PubMed ID: 21139643
[TBL] [Abstract][Full Text] [Related]
9. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
10. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Huang CY; Pu YS; Yu CC; Huang CH
Prostate; 2011 Aug; 71(11):1189-97. PubMed ID: 21656829
[TBL] [Abstract][Full Text] [Related]
11. [Castration of prostate cancer patients and cognition].
Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
[No Abstract] [Full Text] [Related]
12. [Gene expression profile in hormone refractory prostate cancer].
Stoss O; Jost N; Czeloth K; Rüschoff J; Henkel T; Albers P
Urologe A; 2007 Sep; 46(9):1117-9. PubMed ID: 17639295
[No Abstract] [Full Text] [Related]
13. [Diagnosis and treatment of early prostate cancer].
Kaprin AD; Khalil Farzat M; Gafanov RA; Kostin AA
Vopr Onkol; 2009; 55(3):382-5. PubMed ID: 19670743
[No Abstract] [Full Text] [Related]
14. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
[TBL] [Abstract][Full Text] [Related]
15. Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy.
Mignogna MD; Fortuna G; Leuci S; Adamo D; Ruoppo E
Br J Dermatol; 2009 Feb; 160(2):468-70. PubMed ID: 19120335
[No Abstract] [Full Text] [Related]
16. [Early versus late hormonal treatment in advanced prostate cancer].
Allepuz Losa C; Gil Martínez P; Gil Sanz MJ; Rioja Sanz LA
Actas Urol Esp; 1999; 23(7):557-64. PubMed ID: 10488608
[No Abstract] [Full Text] [Related]
17. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
18. [Paraneoplastic syndromes in urology].
Pérez Arbej JA; Nogueras Gimeno MA; Martínez Pérez E; Abad Menor F; Arnáiz Esteban F; Fernández Rosaénz J; Guinda Sevillano C; Espuela Orgaz R
Arch Esp Urol; 1991 Oct; 44(8):943-9. PubMed ID: 1796856
[TBL] [Abstract][Full Text] [Related]
19. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
20. Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
Spratt DE; Tward JD
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):899-902. PubMed ID: 32928598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
